Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration.
Seven patients with advanced colon cancer, refractory to conventional chemotherapy, and malignant disease confined to the intra-abdominal space received a total of 24 consecutive courses of ip 5-Fluorouracil (5-FU). 5-FU 1000 mg was administered in 2 L of warm (37 degrees C) dialysate daily for five consecutive days every 28 days. 5-FU concentrations in serum, peritoneal fluid and urine were measured by high pressure liquid chromatography (HPLC). The mean disappearance half-life of 5-FU from the peritoneal fluid was 1.6 hours with a mean permeability area product (PA) of 22.4 ml/min. The mean peritoneal AUC was 450 +/- 165 times greater than the mean serum AUC. Ip 5-FU treatment is well tolerated, can be safely administered on an outpatient basis and produces a significant pharmacological advantage over conventional routes of administration.
Campora
E
E
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Esposito
M
M
Civalleri
D
D
Gogioso
L
L
Decian
F
F
Balletto
N
N
Falcone
A
A
Nobile
M T
MT
Parodi
B
B
Cafaggi
S
S
D000328:Adult; D001202:Ascitic Fluid / Q000378:metabolism; D002404:Catheterization; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005472:Fluorouracil / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine; D006801:Humans; D007274:Injections, Intraperitoneal; D008875:Middle Aged
D005472:Fluorouracil